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Background: The effect of acetylsalicylic acid (ASA) may be measured through the analysis of urinary concentra-
tions of 11-dehydrothromboxane B2 (11-dhTXB2), a metabolite of thromboxane A2, which is a potent platelet
aggregant agent. It has been suggested thatmetformin (an oral antidiabetic drug) could improve oxidative stress
and control platelet activation in type 2 diabetic patients, potentially reducing cardiovascular risk. We deter-
mined the concentrations of urinary 11-dhTXB2 in type 2 diabetic patients taking ASA and its concentrations
with metformin use and several other clinical variables (hypertension, age, gender, smoking, body mass index,
insulin and statin use), considering a reduction of at least 75% in the concentrations of this marker as a target,
compared to results before ASA intake.
Methods: Urinary concentrations of 11-dhTXB2 of 81 type 2 diabetic patients were measured before and at
15 days taking 100 mg of aspirin daily.
Results:Most patients who presented a reduction of 11-dhTXB2 above 75% were under metformin use. This re-
duction was achieved in 51.5% of patients taking this drug, against 20.0% in the patients who were not
(p = 0.027). The analysis of the other variables did not show a signiﬁcant difference. The use of metformin ap-
pears to play a role in the reduction of 11-dhTXB2 concentrations in type 2 diabetic patients.
Conclusion:According to previous reports, hyperglycemia control seems to be a determinant factor for the success
of ASA therapy, given the inﬂuence of metformin in the reduction of 11-dhTXB2 concentrations.© 2013 Elsevier B.V. All rights reserved.1. Introduction
Diabetes mellitus type 2 is a metabolic disorder largely associated to
microvascular and macrovascular complications and an enhanced risk
for cardiovascular disease (CVD). Several clinical variables, including
hypertension, hyperglycemia, dyslipidemia, C-reactive protein and
body mass index, increase the risk of late complications [1]. According
to International Diabetes Federation, cardiovascular disease is the
major cause of mortality and morbidity in type 2 diabetic patients,
which is conﬁrmed by several epidemiological reports [2].
Acetylsalicylic acid (ASA), a nonsteroidal anti-inﬂammatory drug, is
the most commonly antiplatelet agent used due to its low cost and rel-
ative lack of adverse effects, when administered in low doses [3].
It impairs the platelet formation of thromboxane A2, a potent vasocon-
strictor and platelet aggregant agent, through the acetylation ofnalysis Department, Faculty of
venida Antônio Carlos, 6627,
l. Tel.: +55 3189056559.
lva).
ghts reserved.cyclooxygenase 1 (COX-1) in the serine-530 position, thus preventing
the aracdonic acid binding to the enzymatic active site. Since this inhi-
bition is irreversible, and platelets have no DNA, they are no longer
able to produce new COX enzymes [4–6].
Metformin, an oral antidiabetic drug, iswidely used by type2 diabet-
ic patients as an auxiliary therapy for control of hyperglycemia. It is clas-
siﬁed as a biguanide, and its mechanism of action is related to both a
decrease in hepatic glucose production and intestinal absorption, as an
enhancement in insulin sensitivity due to increase in peripheral glucose
uptake and utilization [7].
2. Methods
2.1. Patients
Eighty-one type 2 diabetic patients were enrolled at this study,
according to the following inclusion criteria: (1) diagnosis of diabe-
tes mellitus type 2, made under the American Diabetes Association
(ADA, 2006) criteria: ≥2 fasting glucose ≥126 mg/dl; random
glucose ≥ 200 mg/dl; oral glucose tolerance curve ≥ 200 mg/dl at
Table 2
Reduction of urinary 11-dhTXB2 levels in type 2 diabetic patients undermetformin intake.
Reduction in urinary 11-dhTXB2 levels
≥75% b75% Total
Metformin intake 34 (51.5%) 32 (48.8%) 66
No metformin intake 3 (20%) 12 (80%) 15
Total 37 (45.7%) 44 (54.3%) 81
p = 0.027, by Pearson χ2; OR = 4.25.
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the intake of ASA immediately after the ﬁrst urine collection. The
exclusion criteria were: use of nonsteroidal anti-inﬂammatory
drugs (NSAIDs), steroidal anti-inﬂammatory drugs, antiplatelet
agents, oral anticoagulant agents, heparin and antiacids; chronic
kidney disease, hepatic insufﬁciency, acute infectious disease, in-
ﬂammatory, autoimmune or myeloproliferative disease; surgery in
the last 6 months or pregnancy.
After the ﬁrst urine collection, all patients started therapy consisting
in taking 100 mg of ASA daily. After 15 days, another urine sample was
collected. The urine samples were obtained from the ﬁrst morning
urine, or after 4 h of urinary retention. The samples were centrifuged
at 1500 rpm for 10 min and the supernatantswere aliquoted and stored
at−80 °C until the analysis moment.
2.2. Clinical data
Data referring to drug intake such as oral antidiabetic drugs, insulin
and statin, besides the epidemiologic and clinical variables, as gender,
age, smoking habit, BMI and hypertension (individuals in use of antihy-
pertensive drugs were classiﬁed as hypertensive [8]) were obtained
from clinical records.
2.3. Analysis
The 11-dhTXB2 quantiﬁcation was made by an immunoenzymatic
assay (ELISA), using the 11-dehydrothromboxane B2 EIA kit (Cayman
Chemical Co.) following the fabricant instructions. This assay is
based on the competition between the 11-dhTXB2 and the conjugate
11-dehydroTXB2-acethilcholinesterase (ACE) for a limited number of
binding sites of rabbit anti-serum speciﬁc for 11-dhTXB2. The concen-
tration of the conjugate is constant, and its binding to the sites is in-
versely proportional to the concentration of 11-dhTXB2 in the sample.
The quantiﬁcation of urinary creatinine (for standardization of the
results, expressed as pg of 11-dhTXB2/mg of creatinine) was carried
out by a kinetic-colorimetric method, according to kit's manufacturer
instructions. The statistical analysis was performed by using Pearson
χ2 test, and a b0.05 was signiﬁcant between groups.
3. Results
Among the 81 patients enrolled at the study, 66 (81.5%) were under
metformin use, and 42 (52%)were using bothmetformin and insulin. In
the group of patients undermetformin use, a reduction of at least 75% in
concentrations of 11-dhTXB2was found in 51.5% of them, against 20% inTable 1
Urinary 11-dhTXB2 levels before and at 15 days of ASA therapy according to gender, hyperten




Men (n = 23) 151.00 (104.00–205.00) 52.00
Women (n = 58) 204.00 (130.75–319.75) 51.00
p⁎⁎ 0.107 0.814
Hypertensive (n = 69) 179.00 (117.50–284.50) 52.00
Nonhypertensive (n = 12) 179.50 (60.75–314.75) 46.50
p⁎⁎ 0.852 0.563
Smokers (n = 9) 268.00(215.00–477.00) 68.00
Ex-smokers (n = 18) 179.50 (97.50–276.75) 64.00
Nonsmokers (n = 54) 164.00 (117.00–283.75) 45.50
p⁎⁎⁎ 0.165 0.201
BMI ≤ 25 kg/m2 (n = 18) 163.00 (82.50–210.75) 63.00
BMI 26–30 kg/m2 (n = 21) 174.00 (101.00–335.00) 51.00
BMI N 30 kg/m2 (n = 42) 208.00 (147.50–147.50) 48.00
p⁎⁎⁎ NS NS
IQR = Interquartile range.
⁎ Wilcoxon test.
⁎⁎ Mann–Whitney test.
⁎⁎⁎ Kruskal–Wallis test.the patients who were not in use of this oral antidiabetic drug
(p = 0.027; OR = 4.25). For other drugs such as insulin and statin as
well as epidemiologic/clinical variables, including gender, age, smoking
habit, hypertension and BMI no differencewas observed as groupswere
compared (Tables 1–3).
4. Discussion
Based on the results, among all variables evaluated in this study, the
use of metformin, an oral antidiabetic drug, seems to be that of greatest
inﬂuence in the reduction of urinary 11-dhTXB2 concentrations in type
2 diabetic patients under ASA therapy.
The associated therapywith these 2 drugs appears to enhance the ef-
fect of ASA due to a reduced platelet activity induced bymetformin use.
Metformin intake is frequent by type 2 diabetic patients as an auxiliary
therapy for improving glycemic control in addition to diet and insulin
use. According to previous reports, metformin by itself shows an
antiaggregant activity, which can explain the reduction of 11-dhTXB2
excretion [7]. The mechanism of action of ASA, by which it irreversibly
impairs the TXA2 formation is well known, but there are still controver-
sies about the mechanism by which metformin reduces platelet aggre-
gation. It is likely that this occurs through reduction in oxidative
stress, but the antioxidant activity of metformin is not fully understood.
It is suggested that hyperglycemia enhances the generation of reactive
oxygen species, which can lead to generation of several active
prostanoids that stimulates platelet activation [7]. These facts strongly
suggest that an indirect pharmacological synergismmay occur between
these drugs, which may be explored in the development of new thera-
peutic schemes for type 2 diabetes treatment and in prevention of
type 2 diabetes complications.
Although the other variables observed in this study do not provide
conclusive data about their contribution in the achievement of the uri-
nary 11-dhTXB2 reduction goal, they are very important for the prog-
nostic of type 2 diabetes and its associated complications and should
always be considered in patients' management.sion, smoking habit and BMI.
n (IQR) 11-dhTXB2 after aspirin
(pg/mg creatinine)
p⁎ Reduction (%) p
(33.00–70.00) 0.00 66 0.026⁎⁎
(32.00–80.25) 0.00 75
(33.50–81.00) 0.00 71 NS⁎⁎
(22.75–76.75) 0.015 74
(34.00–161.50) 0.021 75 NS⁎⁎
(42.75–88.25) 0.001 64
(31.75–72.00) 0.00 72




Association of the reduction in urinary 11-dhTXB2 levels with gender, age, BMI, hyperten-
sion, insulin, statin use and smoking habit.
Reduction in 11-dhTXB2 urinary levels
≥75% b75% Total
Gender
Women 30 (51.7%) 28 (48.3%) 58
Men 7 (30.4%) 16 (69.6%) 23
p = NS by Pearson χ2 test
Age
b50 y 5 (29.4%) 12 (70.6%) 17
≥50 y 32 (50%) 32 (50%) 64
p = NS by Pearson χ2 test
BMI
b25 kg/m2 6 (30%) 14 (70%) 20
25–30 kg/m2 11 (44%) 14 (56%) 25
N30 kg/m2 20 (55.6%) 16 (44.4%) 36
p = NS by Pearson χ2 test
Hypertension
No 6 (50%) 6 (50%) 12
Yes 31 (44.9%) 38 (55.1%) 69
p = NS by Pearson χ2 test
Statin
Yes 22 (48.9%) 23 (51.1%) 17
No 15 (41.7%) 21 (58.3%) 64
p = NS by Pearson χ2 test
Insulin
Yes 21 (42%) 29 (58%) 50
No 16 (51.6%) 15 (48.4%) 31
p = NS by Pearson χ2 test
Smoking
Non-smoker 25 (46.3%) 29 (53.7%) 54
Ex-smoker 7 (38.9%) 11 (61.1%) 18
Smoker 5 (55.6%) 4 (44.4%) 9
p = NS by Pearson χ2 test
Total 37 (45.7%) 44 (54.3%) 81
78 L.H. Gonçalves et al. / Clinica Chimica Acta 429 (2014) 76–78It has been reported that elevated blood pressure can activate plate-
lets, resulting in less efﬁcacy of a standard dose of ASA [9,10]. Likewise,
age contributes to greater platelet activation [11]. Similarly, platelet ac-
tivation was higher in smoker and obese patients [12,13]. Concerning
the gender, it is related that women respond less to ASA therapy than
men [14], although this studywas unable to conﬁrm this result. Regard-
ing insulin and statin use, a reduction in platelet activation in patients
under use of these drugs has been reported by literature [15,16]. In
the present study, this reduction does not reach a signiﬁcant concentra-
tion, although a slight tendency was observed. The absence of signiﬁ-
cant difference for the variables age, gender, BMI, insulin and statin
use may be attributed to the sample size, that is considered as a limita-
tion of the study. However, the present study was able to identify the
potential beneﬁt of an oral antidiabetic drug use on the reduction of
platelet activation, which can be translated by a reduction of ≥75% inurinary 11-dhTXB2 concentrations. A greater reduction in urinary 11-
dhTXB2 concentrations was observed in patients whose baseline con-
centrations of this biomarker were higher, such as women, smokers
and individuals with BMI N30 kg/m2 compared to men, non-smoker
and patients with BMI b25 kg/m2, respectively.
Based on theseﬁndings, it is possible to suggest that a good glycemic
controlmay bedecisive for decreasingplatelet activation and enhancing
ASA efﬁcacy, which may contribute to prevent atherothrombotic
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